Evidence map›Paper›PMID 28795155›Full record

ArticleHepatoma research2017

Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.

Hie-Won Hann, Surbhi Jain, Grace Park, Jamin D Steffen, Wei Song, Ying-Hsiu Su

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatoma research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023
    Review
  12. Article
  13. Circulating tumour DNA - looking beyond the blood.Nature reviews. Clinical oncology · 2022
    Review
  14. [Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hie-Won HannLiver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Surbhi JainJBS Science, Inc., Doylestown, PA 18902, USA.
Grace ParkLiver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Jamin D SteffenJBS Science, Inc., Doylestown, PA 18902, USA.
Wei SongJBS Science, Inc., Doylestown, PA 18902, USA.
Ying-Hsiu SuThe Baruch S. Blumberg Institute, Doylestown, PA 18902, USA.
JBS Science (United States) · USThomas Jefferson University Hospital · USBaruch S. Blumberg Institute · US

Funding

Development of a Urine Test for the Early Detection of Liver CancerR44CA165312 · NCI · JBS SCIENCE, INC. · PI LIN, SELENA · 2013 to 2020
$4.9M
Development of cell-free DNA assays for HCC screening and liquid biopsyR01CA202769 · NCI · BARUCH S. BLUMBERG INSTITUTE · PI SU, YING-HSIU · 2016 to 2020
$2.1M
Urine DNA Kit for monitoring HCC recurrenceR43CA213610 · NCI · JBS SCIENCE, INC. · PI JAIN, SURBHI · 2016 to 2016
$300k
Detection of major HBV integration sites in urine as a biomarker for HBV-associated liver cancerR43CA192507 · NCI · U-SCREEN DX, INC. · PI SONG, WEI · 2015 to 2015
$252k
NCI NIH HHS R01 CA202769NCI NIH HHS R43 CA192507NCI NIH HHS R43 CA213610NCI NIH HHS R44 CA165312
6 · The paper itself

Abstract

aimThis study aimed to explore the potential of detecting hepatocellular carcinoma (HCC)-associated DNA markers,

methodsHere, the authors followed 10 patients that were treated for a primary HCC, and monitored for months or years later. At these follow-up visits, urine was collected and tested retrospectively for 3 DNA biomarkers that associate with HCC development.

resultsThis 10-patient study compared detection of urine DNA markers with MRI for monitoring HCC recurrence. Five patients were confirmed by MRI for recurrence, and all 5 had detectable DNA biomarkers up to 9 months before recurrence confirmation by MRI.

conclusionOverall, this suggests that detection of HCC-associated DNA markers in urine could provide a promising tool to complement detection of recurrent HCC by imaging.

Indexed as

biomarkercirculating-tumor DNAhepatitis B virusHepatocellular carcinomaliver cancerrecurrenceurine tumor marker

Identifiers

PMID28795155
PMCPMC5546802
OpenAlexW2623950679

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.